United Therapeutics | UTHR - Cost Of Sales

Stock Price
485.36
Daily Change
6.43 1.34%
Monthly
-3.64%
Yearly
39.59%
Q1 Forecast
455.03

United Therapeutics reported $100.9M in Cost of Sales for its fiscal quarter ending in September of 2025.





Cost Of Sales Change Date
Amarin USD 16.89M 18.51M Mar/2025
Ardelyx USD 3.98M 10.84M Sep/2025
Baxter International USD 1.88B 66M Sep/2025
Bayer EUR 4.31B 57M Sep/2025
Biogen USD 810.1M 205.1M Sep/2025
BioMarin Pharmaceutical USD 144.93M 10M Sep/2025
Gilead Sciences USD 1.57B 68M Sep/2025
GlaxoSmithKline GBP 2.61B 377M Dec/2025
Halozyme Therapeutics USD 73M 8.88M Sep/2025
Insmed USD 30.9M 1.56M Sep/2025
Ionis Pharmaceuticals USD 2.34M 1.81M Sep/2025
J&J USD 7.97B 689M Dec/2025
Moderna USD 207M 88M Sep/2025
Pfizer USD 6.29B 2.12B Dec/2025
PTC Therapeutics USD 23.32M 7.83M Sep/2025
Regeneron Pharmaceuticals USD 584.6M 63M Dec/2025
Sarepta Therapeutics USD 151.45M 1.77M Sep/2025
Teva Pharmaceutical Industries USD 2.06B 120M Dec/2025
United Therapeutics USD 100.9M 74.3M Sep/2025
Vertex Pharmaceuticals USD 414.8M 7.3M Sep/2025